Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met once inventory was available [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue from these products [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower adoption than forecasted [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Boston Scientific (BSX) is viewed positively for both short-term and long-term prospects, being considered one of the best investment ideas in the medical devices sector [1]. Company Analysis - The company operates within the medical devices industry, which is characterized by significant growth potential and innovation [1]. - Boston Scientific is recognized for its strong fundamentals and ability to uncover hidden value, making it an attractive option for investors [1]. Market Context - The medical devices sector is experiencing robust demand, driven by advancements in technology and an increasing focus on healthcare solutions [1]. - Investment opportunities in this sector are expected to grow, particularly for companies like Boston Scientific that demonstrate strong performance and strategic positioning [1].

Core Viewpoint - Boston Scientific (BSX) is viewed positively for both short-term and long-term investment prospects, being considered one of the best investment ideas in the medical devices sector [1]. Company Analysis - The company operates within the medical devices industry, which is characterized by significant growth potential and innovation [1]. - Boston Scientific is recognized for its strong fundamentals and ability to uncover hidden value, making it an attractive option for investors [1]. Market Context - The medical devices sector is experiencing robust demand, driven by advancements in technology and an increasing focus on healthcare solutions [1]. - Investment opportunities in this sector are expected to continue growing, positioning companies like Boston Scientific favorably in the market [1].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case, with claims made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while actual demand and revenue had sharply declined, contradicting public assurances [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met with sufficient inventory [5]. - Contrary to these assurances, Inspire failed to adequately prepare clinicians and payors, leading to significant delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which did not meet expectations and was marred by operational failures [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [1]. - The complaint alleges that the launch of Inspire V was unsuccessful due to poor demand, with providers holding excess inventory and being hesitant to adopt the new treatment [2]. - Defendants are accused of making false statements regarding the successful launch of Inspire V, despite failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Growth investors are attracted to stocks with above-average financial growth, but identifying stocks that can sustain this growth is challenging due to associated risks and volatility [1] Group 1: Company Overview - Insulet (PODD) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company specializes in insulin infusion systems, which positions it well in the healthcare sector [3] Group 2: Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 51% this year, significantly surpassing the industry average of 11.2% [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Insulet is 17.4%, exceeding the industry average of 3.5% [5] - Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.9% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Insulet have been revised upward, with a 0.1% increase in the Zacks Consensus Estimate over the past month [7] Group 5: Investment Potential - Insulet holds a Zacks Rank of 2 and a Growth Score of A, indicating its potential as an outperformer and a solid choice for growth investors [9]

Company Overview - Edwards Lifesciences (EW) received FDA approval for its SAPIEN M3 transcatheter mitral valve replacement system, marking it as the first minimally invasive, catheter-based treatment using a transseptal approach for mitral regurgitation [2][4][7] - The SAPIEN M3 system is intended for patients with moderate-to-severe mitral valve leakage who are not candidates for open-heart surgery or existing repair treatments, including those with severe mitral valve dysfunction due to calcification [3][4] Clinical Validation - The one-year ENCIRCLE trial data demonstrated a 95.7% elimination rate of mitral regurgitation (MR) and significant improvements in patient symptoms, showcasing the system's safety and effectiveness [7][10] - The SAPIEN M3 system is positioned as a transformative option for treating mitral valve disease in the U.S., enhancing its adoption among physicians [10] Market Position and Growth Potential - The FDA approval is expected to enhance Edwards Lifesciences' growth profile in the mitral valve market by providing a safe and effective treatment for previously untreatable patients, reinforcing its competitive position in minimally invasive heart therapies [8][11] - The heart valve device market is projected to reach $14.89 billion by 2025, with a CAGR of 11.7% through 2034, driven by the increasing prevalence of vascular heart diseases and advancements in minimally invasive procedures [12] Financial Performance - Following the announcement of the SAPIEN M3 approval, Edwards Lifesciences' shares increased by 0.1%, with an 11.9% rise over the past six months, outperforming the industry and the S&P 500 [5] Additional Initiatives - Edwards Lifesciences is sponsoring the American Heart Association's Heart Valve Initiative, aiming to improve care for 28 million people with heart valve disease through early diagnosis, clinician training, and public awareness [13]

WHAT'S NEXT? If you suffered a loss in Inspire Medical Systems, Inc. during the relevant time frame, you have until January 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NEW YORK, Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: ...